Cancer Commons, in partnership with the Musella Foundation For Brain Tumor Research & Information, has a pilot study underway that seeks to improve outcomes for current glioblastoma (GBM) patients and identify promising therapies for development. The study will use genomic sequencing and other biomarker testing to help identify individualized treatment regimens and will capture and analyze clinical outcomes to inform treatment for future patients.
Cancer Commons will provide eligible patients with a case review by a panel of neuro-oncology experts from across the country (which we call the Cancer Commons Virtual Tumor Board), assistance with determining and beginning the next line of treatment, and follow up at regular intervals.
We are enrolling patients who meet specific criteria. Click this link for more information and to register.